43 related articles for article (PubMed ID: 17080308)
1. MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling.
Wasielewski M; Nagel JH; Brekelmans C; Klijn JG; van den Ouweland A; Meijers-Heijboer H; Schutte M
Breast Cancer Res Treat; 2007 Aug; 104(2):153-7. PubMed ID: 17080308
[TBL] [Abstract][Full Text] [Related]
2. Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma.
Firoz EF; Warycha M; Zakrzewski J; Pollens D; Wang G; Shapiro R; Berman R; Pavlick A; Manga P; Ostrer H; Celebi JT; Kamino H; Darvishian F; Rolnitzky L; Goldberg JD; Osman I; Polsky D
Clin Cancer Res; 2009 Apr; 15(7):2573-80. PubMed ID: 19318491
[TBL] [Abstract][Full Text] [Related]
3. An information-theoretic analysis of genetics, gender and age in cancer patients.
Atwal GS; Rabadán R; Lozano G; Strong LC; Ruijs MW; Schmidt MK; van't Veer LJ; Nevanlinna H; Tommiska J; Aittomäki K; Bougeard G; Frebourg T; Levine AJ; Bond GL
PLoS One; 2008 Apr; 3(4):e1951. PubMed ID: 18398474
[TBL] [Abstract][Full Text] [Related]
4. Estrogen and breast cancer: can less mean more?
Bullock MD; Silva AM; Calin GA
Cell Cycle; 2015; 14(14):2197-8. PubMed ID: 26090587
[No Abstract] [Full Text] [Related]
5. Editorial Comment to Prominent response to platinum-based chemotherapy in a patient with
Matsumoto T; Shiota M
IJU Case Rep; 2021 Jul; 4(4):219-220. PubMed ID: 34258531
[No Abstract] [Full Text] [Related]
6. A case-control study on the SNP309T → G and 40-bp Del1518 of the MDM2 gene and a systematic review for MDM2 polymorphisms in the patients with breast cancer.
Jalilvand A; Yari K; Aznab M; Rahimi Z; Salahshouri Far I; Mohammadi P
J Clin Lab Anal; 2020 Dec; 34(12):e23529. PubMed ID: 32951271
[TBL] [Abstract][Full Text] [Related]
7. Association of the
Miedl H; Lebhard J; Ehart L; Schreiber M
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691044
[TBL] [Abstract][Full Text] [Related]
8. The role of MDM2 and MDM4 in breast cancer development and prevention.
Haupt S; Vijayakumaran R; Miranda PJ; Burgess A; Lim E; Haupt Y
J Mol Cell Biol; 2017 Feb; 9(1):53-61. PubMed ID: 28096293
[TBL] [Abstract][Full Text] [Related]
9. Association between MDM2 rs 2279744 polymorphism and breast cancer susceptibility: a meta-analysis based on 9,788 cases and 11,195 controls.
Gao J; Kang AJ; Lin S; Dai ZJ; Zhang SQ; Liu D; Zhao Y; Yang PT; Wang M; Wang XJ
Ther Clin Risk Manag; 2014; 10():269-77. PubMed ID: 24790452
[TBL] [Abstract][Full Text] [Related]
10. Role of two single nucleotide polymorphisms in secreted frizzled related protein 1 and bladder cancer risk.
Rogler A; Hoja S; Socher E; Nolte E; Wach S; Wieland W; Hofstädter F; Goebell PJ; Wullich B; Hartmann A; Stoehr R
Int J Clin Exp Pathol; 2013; 6(10):1984-98. PubMed ID: 24133576
[TBL] [Abstract][Full Text] [Related]
11. Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis.
Cheng H; Ma B; Jiang R; Wang W; Guo H; Shen N; Li D; Zhao Q; Wang R; Yi P; Zhao Y; Liu Z; Huang T
Mol Biol Rep; 2012 Sep; 39(9):9265-74. PubMed ID: 22729912
[TBL] [Abstract][Full Text] [Related]
12. MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer.
Ryan BM; Calhoun KM; Pine SR; Bowman ED; Robles AI; Ambs S; Harris CC
Int J Cancer; 2012 Dec; 131(11):2710-6. PubMed ID: 22487911
[TBL] [Abstract][Full Text] [Related]
13. MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis.
Zhao E; Cui D; Yuan L; Lu W
Mol Biol Rep; 2012 Apr; 39(4):3471-7. PubMed ID: 21725850
[TBL] [Abstract][Full Text] [Related]
14. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.
Wan Y; Wu W; Yin Z; Guan P; Zhou B
BMC Cancer; 2011 May; 11():208. PubMed ID: 21619694
[TBL] [Abstract][Full Text] [Related]
15. Single-nucleotide polymorphisms in the p53 signaling pathway.
Grochola LF; Zeron-Medina J; Mériaux S; Bond GL
Cold Spring Harb Perspect Biol; 2010 May; 2(5):a001032. PubMed ID: 20452958
[TBL] [Abstract][Full Text] [Related]
16. ARLTS1, MDM2 and RAD51 gene variations are associated with familial breast cancer.
Akisik E; Yazici H; Dalay N
Mol Biol Rep; 2011 Jan; 38(1):343-8. PubMed ID: 20358297
[TBL] [Abstract][Full Text] [Related]
17. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
[TBL] [Abstract][Full Text] [Related]
18. The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Sinilnikova OM; Antoniou AC; Simard J; Healey S; Léoné M; Sinnett D; Spurdle AB; Beesley J; Chen X; ; Greene MH; Loud JT; Lejbkowicz F; Rennert G; Dishon S; Andrulis IL; ; Domchek SM; Nathanson KL; Manoukian S; Radice P; Konstantopoulou I; Blanco I; Laborde AL; Durán M; Osorio A; Benitez J; Hamann U; Hogervorst FB; van Os TA; Gille HJ; ; Peock S; Cook M; Luccarini C; Evans DG; Lalloo F; Eeles R; Pichert G; Davidson R; Cole T; Cook J; Paterson J; Brewer C; ; Hughes DJ; Coupier I; Giraud S; Coulet F; Colas C; Soubrier F; Rouleau E; Bièche I; Lidereau R; Demange L; Nogues C; Lynch HT; ; Schmutzler RK; Versmold B; Engel C; Meindl A; Arnold N; Sutter C; Deissler H; Schaefer D; Froster UG; ; Aittomäki K; Nevanlinna H; McGuffog L; Easton DF; Chenevix-Trench G; Stoppa-Lyonnet D;
Br J Cancer; 2009 Oct; 101(8):1456-60. PubMed ID: 19707196
[TBL] [Abstract][Full Text] [Related]
19. Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene.
Atwal GS; Kirchhoff T; Bond EE; Montagna M; Menin C; Bertorelle R; Scaini MC; Bartel F; Böhnke A; Pempe C; Gradhand E; Hauptmann S; Offit K; Levine AJ; Bond GL
Proc Natl Acad Sci U S A; 2009 Jun; 106(25):10236-41. PubMed ID: 19497887
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
